Site-Specific Immunomodulator: A Novel Treatment for Crohn’s Disease

Table 2

Patient response to SSI QBECO treatment.

Patient	QBECO SSI therapy duration	Response while on SSI treatment	Status after SSI treatment	Current medications	Confirmation of ongoing remission
1	11 months	Remission	Ongoing remission 3.8 years	None	Colonoscopy
2	3 months	Remission	Ongoing remission 2.8 years	None	CT scan
3	6 months	Remission	Remission 1.4 years, disease recurrence	Standard care	n/a
4	8 months	Remission, including perianal fistulae	Ongoing remission 2.2 years	None	Colonoscopy
5	3.5 months	Remission	Remission 1.2 years, disease recurrence	Standard care	n/a
6	5 months	Remission	Remission 3 months, disease recurrence	Standard care	n/a
7	7.5 months	Remission	Recurrence post-SSI; Less severe symptoms	Standard care	n/a
8	6.5 months	Improvement	Symptom return post-SSI; Less severe symptoms	Standard care	n/a
9	5 months	Improvement, reduction in prednisone	Symptom return post-SSI	Standard care	n/a
10	2.5 months	Improvement	Symptom return post-SSI	Standard care	n/a

Standard care: patient is being treated by other approved CD drugs.